At European Biopharmaceutical Enterprises (EBE), one of our top priorities has always been to advocate for better access to innovative personalised medicine to help deliver tangible health improvements for EU citizens.
That’s why today we are calling on EU Member States to implement five new policy recommendations for personalised medicine from coherent prioritisation of personalised medicine within existing strategic health plans to collaborative actions for tackling current reimbursement delays. These recommendations come from a new Charles River Associates study that we at EBE commissioned with the European Federation of Pharmaceutical Industries and Associations (EFPIA)* called ‘The benefits of personalised medicine to patients, society and healthcare systems.’
Our five key recommendations include:
- A coherent prioritisation of personalised medicine that goes hand in hand with existing national health strategic plans;
- A continued emphasis on better management of care, coordination of expertise and resources to ensure an adequate “personalisation of care”;
- A continued investment and cooperation in next generation testing infrastructure (such as molecular genetic laboratories) as well as developing dedicated funding pathways to ensure access to diagnostics;
- A consistent diagnostic testing infrastructure throughout Europe;
- A collaboration between regulators and health technology assessment bodies on reimbursement pathways for personalised medicine.
Personalised medicine is about providing tailor-made prevention and treatment strategies for individuals, because it’s clear that ‘one size fits all’ medicines are not helping us to improve the efficacy of medical treatments for many EU patients. People with apparently the same clinical diagnosis or symptoms often have different responses to the same treatment. However, thanks to personalised medicine we are now better able to provide patients with the most appropriate treatments. The study published today explains the evidence on how this approach results in benefits for patients, health care systems, and the development on future medicines.
But Members States still are not doing enough to provide access to these more specific innovative medicines. Finding answers to these challenges has been the goal of our Working Group on Personalised Medicine, which was started at EBE in 2010 and in 2015 became a joint group with EFPIA.
Our hope is that this study will help provide the incentive need to move personalised medicine to the top of agenda in Europe, so that all EU citizens can benefit.
* Financed by voluntary contributions from the following EBE and EFPIA members: Association Innovative Medicines (National pharmaceutical industry association of the Netherlands), AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Genomic Health, Merck KGaA, Novartis, Roche, Roche Diagnostics
Executive Director, EBE